Literature DB >> 32930581

Targeting Lipid Metabolism in Liver Cancer.

Malak Alannan1,2, Hussein Fayyad-Kazan3, Véronique Trézéguet1, Aksam Merched1.   

Abstract

Cancer cells are highly dependent on different metabolic pathways for sustaining their survival, growth, and proliferation. Lipid metabolism not only provides the energetic needs of the cells but also provides the raw material for cellular growth and the signaling molecules for many oncogenic pathways. Mainly processed in the liver, lipids play an essential role in the physiology of this organ and in the pathological progression of many diseases such as metabolic syndrome and hepatocellular carcinoma (HCC). The progression of HCC is associated with inflammation and complex metabolic reprogramming, and its prognosis remains poor because of the lack of effective therapies despite many years of dedicated research. Defects in hepatic lipid metabolism induce abnormal gene expression and rewire many cellular pathways involved in oncogenesis and metastasis, implying that interfering with lipid metabolism within the tumor and the surrounding microenvironment may be a novel therapeutic approach for treating liver cancer patients. Therefore, this review focuses on the latest advances in drugs targeting lipid metabolism and leading to promising outcomes in preclinical studies and some ongoing clinical trials.

Entities:  

Mesh:

Year:  2020        PMID: 32930581     DOI: 10.1021/acs.biochem.0c00477

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  9 in total

1.  Novel Thienopyrimidines as Acetyl-CoA Carboxylase Inhibitors for Treating Liver Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-04-27       Impact factor: 4.345

2.  Hsa_Circ_0098181 Suppresses Hepatocellular Carcinoma by Sponging miR-18a-3p and Targeting PPARA.

Authors:  Yuan-Yuan Luo; Ke-Gong Tao; Yi-Ting Lu; Bin-Bin Li; Kai-Ming Wu; Chen-Hong Ding; Fang-Zhi Yan; Yue Liu; Yong Lin; Xin Zhang; Xin Zeng
Journal:  Front Pharmacol       Date:  2022-02-21       Impact factor: 5.810

3.  Smilax china root extract as a novel Glucose- 6-phosphate dehydrogenase inhibitor for the treatment of hepatocellular carcinoma.

Authors:  Lubna Kanwal; Shaukat Ali; Azhar Rasul; Hafiz Muhammad Tahir
Journal:  Saudi J Biol Sci       Date:  2022-07-30       Impact factor: 4.052

Review 4.  Posttranslational control of lipogenesis in the tumor microenvironment.

Authors:  Yahui Zhu; Xingrong Lin; Xiaojun Zhou; Edward V Prochownik; Fubing Wang; Youjun Li
Journal:  J Hematol Oncol       Date:  2022-08-29       Impact factor: 23.168

Review 5.  SP and KLF Transcription Factors in Cancer Metabolism.

Authors:  Emilia J Orzechowska-Licari; Joseph F LaComb; Aisharja Mojumdar; Agnieszka B Bialkowska
Journal:  Int J Mol Sci       Date:  2022-09-01       Impact factor: 6.208

6.  A metabolism-associated gene signature for prognosis prediction of hepatocellular carcinoma.

Authors:  Yilin Tian; Jing Lu; Yongxia Qiao
Journal:  Front Mol Biosci       Date:  2022-09-30

7.  A risk signature based on necroptotic-process-related genes predicts prognosis and immune therapy response in kidney cell carcinoma.

Authors:  Jingxian Li; Xun Liu; Yuanjiong Qi; Yang Liu; E Du; Zhihong Zhang
Journal:  Front Immunol       Date:  2022-09-16       Impact factor: 8.786

8.  Distinctive Metabolism-Associated Gene Clusters That Are Also Prognostic in Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma.

Authors:  Linchao Ding; Shilong Ning; Weijian Hu; Yadong Xue; Shi'an Yu
Journal:  Oxid Med Cell Longev       Date:  2022-09-19       Impact factor: 7.310

Review 9.  Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism.

Authors:  Véronique Trézéguet; Hala Fatrouni; Aksam J Merched
Journal:  Cells       Date:  2021-12-09       Impact factor: 6.600

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.